Independent Scientific Sponsorship Grant Focused on Healthcare Quality Improvement
Independent Scientific Sponsorship Grant Focused on Healthcare Quality Improvement supports healthcare organizations in clinician education and care improvements to better identify, diagnose, and treat hypertension.
Funder: AstraZeneca United States
Due Dates: Rolling review beginning January 5, 2027 (grant decisions) | February 1–August 1, 2027 (anticipated project starts)
Funding Amounts: Up to $50,000 per request to offset quality improvement initiative expenses
Summary: Supports clinician education and clinical quality improvement initiatives addressing identification, diagnosis, and treatment of uncontrolled or resistant hypertension.
Key Information: Initiatives must be educational and non-promotional; scientific research, implementation science, and precision medicine projects are out of scope.
Description
AstraZeneca United States, through its Medical Education Grants Office (MEGO), supports healthcare quality improvement initiatives that optimize the identification, diagnosis, and treatment of uncontrolled or resistant hypertension in clinical settings. The focus is patients whose blood pressure remains above goal despite taking two or more antihypertensive medications. Proposals must include a strong clinician education component and demonstrate its impact through project outcomes and reported metrics.
The program seeks initiatives grounded in an assessment of care gaps, barriers, and opportunities, with a clearly defined improvement aim and an action plan incorporating education development and dissemination. Projects should measure whether changes improve care, sustain improvements within routine practice, and share lessons to encourage awareness and adoption. This opportunity supports healthcare quality improvement rather than scientific research, implementation science studies, or precision medicine projects.
